The use of depot medications in the treatment of schizophrenia

American Journal of Psychiatry

Volumn 167, Issue 2, 2010, Pages 125-126

  Davis, John M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

CLINICAL PRACTICE; CLINICAL STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; DRUG USE; EDITORIAL; MAINTENANCE THERAPY; MEDICAL LITERATURE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PUBLICATION; RELAPSE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; SCHIZOPHRENIA;

EID: 75749132020     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09111676     Document Type: Editorial

References (5)

1. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010; 167:181-189
2. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163:185-194
3. Davis JM, Chen N, Glick ID: Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology 2008; 33:971-975
4. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA: Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163:2090-2095
5. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L: Depot antipsychotic drugs: place in therapy. Drugs 1994; 47:741-773